Concepedia
Statistics
Publications
13
Citations
1.9K
H-Index
Active since
1992
Affiliations
Research Triangle Park Foundation(Current)
GlaxoSmithKline (United States)
University of Colorado Denver
GlaxoSmithKline (United Kingdom)
University of California San Diego
Kenneth M. Kral is an author at Research Triangle Park Foundation specializing in pharmacotherapy, pharmacology, and medicine.
Publications per year
1992–2019
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
David B. Badesch, Victor F. Tapson, Michael D. McGoon et al. · Annals of Internal Medicine · 2000 · 1.1K citations
Medicine, Pharmacotherapy, Cardiopulmonary Rehabilitation +10
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone
David A. Stempel, Ibrahim Raphiou, Kenneth M. Kral et al. · New England Journal of Medicine · 2016 · 156 citations · Full text
Pharmacy, Pharmacology, Pharmacotherapy +15
Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma
David A. Stempel, Stanley J. Szefler, Søren Pedersen et al. · New England Journal of Medicine · 2016 · 137 citations · Full text
Pharmacy, Pediatrics, Pharmacotherapy +17
No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year.
David B. Allen, Eli O. Meltzer, Robert F. Lemanske et al. · PubMed · 2003 · 131 citations
Medicine, Pediatrics, Pharmacology +17
Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol
David B. Badesch, Michael D. McGoon, Robin J. Barst et al. · The Journal of Rheumatology · 2009 · 86 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +11
1–5 of 13